Orexo AB Asset Resilience Ratio
Orexo AB asset resilience ratio. Orexo AB (ORX) has an Asset Resilience Ratio of 0.00% as of September 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Orexo AB liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Orexo AB (2005–2023)
Asset resilience ratio of Orexo AB from 2005 to 2023. This chart shows how Orexo AB's Asset Resilience Ratio has changed over time. Read ORX total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Orexo AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see ORX asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 0% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Orexo AB maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Orexo AB Industry Peers by Asset Resilience Ratio
Compare Orexo AB's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 11.84% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976 |
Drug Manufacturers - Specialty & Generic | 20.61% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.42% |
Orexo AB Asset Resilience Ratio by Year (2005–2023)
Orexo AB asset resilience ratio by year from 2005 to 2023. The table below shows the annual Asset Resilience Ratio data for Orexo AB.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.00% | Skr0.00 ≈ $0.00 |
Skr786.60 Million ≈ $84.65 Million |
-- |
| 2022-12-31 | 19.80% | Skr219.60 Million ≈ $23.63 Million |
Skr1.11 Billion ≈ $119.35 Million |
+19.81pp |
| 2015-12-31 | 0.00% | Skr-40.00K ≈ $-4.30K |
Skr1.02 Billion ≈ $109.37 Million |
-14.78pp |
| 2006-12-31 | 14.77% | Skr56.13 Million ≈ $6.04 Million |
Skr379.93 Million ≈ $40.89 Million |
-9.37pp |
| 2005-12-31 | 24.14% | Skr89.63 Million ≈ $9.65 Million |
Skr371.31 Million ≈ $39.96 Million |
-- |
About Orexo AB
Orexo AB (publ), a pharmaceutical company, provides advance treatments for severe diseases and life-saving rescue medications in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; Edluar for the treatment of insomnia; and Diabac… Read more